Overview of lymphoma diagnosis and management.

The malignant lymphomas, including both Hodgkin lymphoma (HL) and non-Hodgkin lymphoma (NHL), represent a diverse group of diseases that arise from a clonal proliferation of lymphocytes. Each of the more than 30 unique types of lymphoma is a disease with a distinct natural history. This biologic heterogeneity gives rise to marked differences among the lymphomas with respect to epidemiology, pathologic characteristics, clinical presentation, and optimal management. This article emphasizes the principles of diagnosis, including appropriate pathologic evaluation and staging considerations, and focuses on the clinical presentation, staging, and optimal management strategies for the most common types of lymphoma.

[1]  M. Rosenblum,et al.  Paraneoplastic cerebellar degeneration , 1992, Neurology.

[2]  H. Rappaport,et al.  Morphological criteria in the classification of the malignant lymphomas. , 1970, Proceedings. National Cancer Conference.

[3]  J. Piette,et al.  Increased risks of lymphoma and death among patients with non-hepatitis C virus-related mixed cryoglobulinemia. , 2006, Archives of internal medicine.

[4]  G. Klein,et al.  Epstein–Barr Virus in Burkitt's Lymphoma and Nasopharyngeal Carcinoma: Antibodies to EBV associated Membrane and Viral Capsid Antigens in Burkitt Lymphoma Patients , 1970, Nature.

[5]  A. Zelenetz,et al.  NCCN: Non-Hodgkin's lymphoma. , 2001, Cancer control : journal of the Moffitt Cancer Center.

[6]  A. Bezjak,et al.  Stage I and II MALT lymphoma: results of treatment with radiotherapy. , 2001, International journal of radiation oncology, biology, physics.

[7]  L. Staudt,et al.  Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. , 2004, Blood.

[8]  C. Mayr,et al.  High-dose chemotherapy followed by autologous stem cell transplantation as first-line therapy in aggressive non-Hodgkin's lymphoma: a meta-analysis. , 2003, Haematologica.

[9]  N. Ueno,et al.  Reduced-intensity allogeneic stem cell transplantation in relapsed and refractory Hodgkin's disease: low transplant-related mortality and impact of intensity of conditioning regimen , 2005, Bone Marrow Transplantation.

[10]  A. Zelenetz,et al.  Autologous transplantation for relapsed or primary refractory peripheral T‐cell lymphoma , 2006, British journal of haematology.

[11]  C. Paolo,et al.  Hematopoietic stem cell transplantation in peripheral T-cell lymphomas , 2007, Leukemia & lymphoma.

[12]  V. Diehl,et al.  Clinical presentation, course, and prognostic factors in lymphocyte-predominant Hodgkin's disease and lymphocyte-rich classical Hodgkin's disease: report from the European Task Force on Lymphoma Project on Lymphocyte-Predominant Hodgkin's Disease. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  A. Zelenetz,et al.  Histologic transformation of follicular lymphoma to diffuse lymphoma represents tumor progression by a single malignant B cell , 1991, The Journal of experimental medicine.

[14]  W. Blattner,et al.  Clinical course of retrovirus-associated adult T-cell lymphoma in the United States. , 1983, The New England journal of medicine.

[15]  A. Zelenetz,et al.  Effectiveness of high dose chemoradiotherapy and autologous stem cell transplantation for patients with biopsy‐proven primary refractory Hodgkin's disease , 2004, British journal of haematology.

[16]  M. Paulli,et al.  Nodular lymphocyte predominance Hodgkin's disease: long-term observation reveals a continuous pattern of recurrence. , 1997, Leukemia & lymphoma.

[17]  M. Weinstock,et al.  The changing survival of patients with mycosis fungoides , 1999, Cancer.

[18]  G. Salles,et al.  Mucosa-associated lymphoid tissue lymphoma is a disseminated disease in one third of 158 patients analyzed. , 2000, Blood.

[19]  V. Ambrosini,et al.  18F-FDG PET in mucosa-associated lymphoid tissue (MALT) lymphoma , 2006, Leukemia & lymphoma.

[20]  T. Lister,et al.  Management of localized non‐Hodgkin's lymphoma: The experience at St. Bartholomew's hospital 1972–1985 , 1989, Hematological oncology.

[21]  C. Meijer,et al.  Primary and secondary cutaneous CD 30 1 lymphoproliferative disorders : a report from the Dutch Cutaneous Lymphoma Group on the long-term follow-up data of 219 patients and guidelines for diagnosis and treatment , 2022 .

[22]  K. Beal,et al.  FDG-PET scanning for detection and staging of extranodal marginal zone lymphomas of the MALT type: a report of 42 cases. , 2005, Annals of oncology : official journal of the European Society for Medical Oncology.

[23]  J. Goedert,et al.  Hodgkin lymphoma and immunodeficiency in persons with HIV/AIDS. , 2006, Blood.

[24]  L. Caplan,et al.  Risk factors for non-Hodgkin's lymphoma according to family history of haematolymphoproliferative malignancies. , 2001, International journal of epidemiology.

[25]  S. Pileri,et al.  Alemtuzumab (Campath-1H) and CHOP chemotherapy as first-line treatment of peripheral T-cell lymphoma: results of a GITIL (Gruppo Italiano Terapie Innovative nei Linfomi) prospective multicenter trial. , 2007, Blood.

[26]  Dirk Hasenclever,et al.  Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin's disease: a randomised trial , 2002, The Lancet.

[27]  B. E. C. Oiffier,et al.  CHOP Chemotherapy plus Rituximab Compared with CHOP Alone in Elderly Patients with Diffuse Large-B-Cell Lymphoma , 2002 .

[28]  Y. Shugart,et al.  A genetic study of Hodgkin's lymphoma: an estimate of heritability and anticipation based on the familial cancer database in Sweden , 2000, Human Genetics.

[29]  E. Campo,et al.  Definition, diagnosis, and management of intravascular large B-cell lymphoma: proposals and perspectives from an international consensus meeting. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[30]  N. Harris,et al.  Mediastinal large cell lymphoma: An uncommon subset of adult lymphoma curable with combined modality therapy , 1988, Cancer.

[31]  C. Meijer,et al.  Primary and secondary cutaneous CD30+lymphoproliferative disorders: a report from the Dutch Cutaneous Lymphoma Group on the long-term follow-up data of 219 patients and guidelines for diagnosis and treatment , 2000 .

[32]  T L Chorba,et al.  Trends in non‐hodgkin lymphoma (NHL) and HIV‐associated NHL deaths in the United States , 2001, American journal of hematology.

[33]  S. Pittaluga,et al.  Marginal zone B-cell lymphomas of different sites share similar cytogenetic and morphologic features , 1996 .

[34]  A. Rademaker,et al.  A phase II clinical trial of intensive chemotherapy followed by consolidative stem cell transplant: long‐term follow‐up in newly diagnosed mantle cell lymphoma , 2008, British journal of haematology.

[35]  M Tubiana,et al.  Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin's disease: Cotswolds meeting. , 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[36]  Randy D Gascoyne,et al.  Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[37]  R. Fisher,et al.  Phase III randomized intergroup trial of subtotal lymphoid irradiation versus doxorubicin, vinblastine, and subtotal lymphoid irradiation for stage IA to IIA Hodgkin's disease. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[38]  C. Klemke,et al.  Prognostic factors and prediction of prognosis by the CTCL Severity Index in mycosis fungoides and Sézary syndrome , 2005, The British journal of dermatology.

[39]  M. Stolte,et al.  Long-term follow-up of gastric MALT lymphoma after Helicobacter pylori eradication. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[40]  A. Tsimberidou,et al.  Richter syndrome , 2005, Cancer.

[41]  Ruta Bajorunaite,et al.  Comparison of autologous and allogeneic hematopoietic stem cell transplantation for follicular lymphoma. , 2003, Blood.

[42]  W. Chan,et al.  Clonality in nodular lymphocyte-predominant Hodgkin's disease. , 1997, The New England journal of medicine.

[43]  M. Calaminici,et al.  Risk and clinical implications of transformation of follicular lymphoma to diffuse large B-cell lymphoma. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[44]  M. Piris,et al.  Splenic marginal zone lymphoma: clinical characteristics and prognostic factors in a series of 60 patients. , 2002, Blood.

[45]  S. Horning,et al.  Long-term survival after histologic transformation of low-grade follicular lymphoma. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[46]  K. Franssila,et al.  Predictive factors for blastoid transformation in the common variant of mantle cell lymphoma. , 2003, European journal of cancer.

[47]  E. Jaffe,et al.  The human T-cell leukemia/lymphoma virus associated with American adult T-cell leukemia/lymphoma. , 1983, Blood.

[48]  Edward J. Lee,et al.  Intensive chemotherapy with and without cranial radiation for Burkitt leukemia and lymphoma , 2004, Cancer.

[49]  J. Spivak,et al.  Commentary on and reprint of Wotherspoon AC, Ortiz-Hidalgo C, Falzon MR, Isaacson PG, Helicobacter pylori-associated gastritis and primary B-cell gastric lymphoma, in Lancet (1991) 338:1175–1176 , 2000 .

[50]  R. Siebert,et al.  Familial Hodgkin's and non-Hodgkin's lymphoma: different patterns in first-degree relatives. , 1997, Leukemia & lymphoma.

[51]  S. Pittaluga,et al.  Marginal zone B-cell lymphomas of different sites share similar cytogenetic and morphologic features. , 1996, Blood.

[52]  T. Starzl,et al.  Expression of Epstein-Barr virus-encoded small RNA (by the EBER-1 gene) in liver specimens from transplant recipients with post-transplantation lymphoproliferative disease. , 1992, The New England journal of medicine.

[53]  P. Bastrup-Madsen,et al.  Alcohol pain in Hodgkin's disease. , 1953, Lancet.

[54]  C. Pascutto,et al.  Splenic and nodal marginal zone lymphomas are indolent disorders at high hepatitis C virus seroprevalence with distinct presenting features but similar morphologic and phenotypic profiles , 2004, Cancer.

[55]  M. Djokic Intravascular large B-cell lymphoma (IVLBCL): a clinicopathologic study of 96 cases with special reference to the immunophenotypic heterogeneity of CD5 , 2008 .

[56]  A. Levis,et al.  Emission Tomography Is Prognostically Superior to International Prognostic Score in Advanced-Stage Hodgkin's Lymphoma: A Report From a Joint Italian- , 2007 .

[57]  J. Seymour,et al.  Primary non-Hodgkin's lymphoma of the breast: retrospective analysis of prognosis and patterns of failure in two Australian centers. , 2006, Clinical lymphoma & myeloma.

[58]  L. Staudt,et al.  Gene Expression Signatures Predict Overall Survial in Diffuse Large B Cell Lymphoma Treated with Rituximab and Chop-Like Chemotherapy. , 2007 .

[59]  V. Diehl,et al.  Rituximab in relapsed lymphocyte-predominant Hodgkin lymphoma: long-term results of a phase 2 trial by the German Hodgkin Lymphoma Study Group (GHSG). , 2008, Blood.

[60]  H. Tilly,et al.  Incidence and risk factors of central nervous system relapse in histologically aggressive non-Hodgkin's lymphoma uniformly treated and receiving intrathecal central nervous system prophylaxis: A GELA study on 974 patients , 2000 .

[61]  J. Jais,et al.  Infradiaphragmatic Hodgkin's disease: long term results of combined modality therapy. , 1996, Leukemia & lymphoma.

[62]  H. Kantarjian,et al.  Hyper-CVAD and high-dose methotrexate/cytarabine followed by stem-cell transplantation: an active regimen for aggressive mantle-cell lymphoma. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[63]  R. Gascoyne,et al.  Prognostic significance of Bcl-6 protein expression in DLBCL treated with CHOP or R-CHOP: a prospective correlative study. , 2006, Blood.

[64]  ONSTANZE,et al.  GENOMIC ABERRATIONS AND SURVIVAL IN CHRONIC LYMPHOCYTIC LEUKEMIA , 2010 .

[65]  J. Rodríguez,et al.  Frontline autologous stem cell transplantation in high‐risk peripheral T‐cell lymphoma: a prospective study from The Gel‐Tamo Study Group , 2007, European journal of haematology.

[66]  A. López-Guillermo,et al.  The clinical significance of molecular response in indolent follicular lymphomas. , 1998, Blood.

[67]  P. Cohen,et al.  Bone marrow and peripheral blood involvement in mantle cell lymphoma , 1998, British journal of haematology.

[68]  B. Glimelius,et al.  Infradiaphragmatic Hodgkin's disease: the Swedish National Care Programme experience , 1997, European journal of haematology.

[69]  D. Weisenburger,et al.  Family history of hematopoietic malignancies and risk of non-Hodgkin lymphoma (NHL): a pooled analysis of 10 211 cases and 11 905 controls from the International Lymphoma Epidemiology Consortium (InterLymph). , 2006, Blood.

[70]  G. Palestro,et al.  Intrasinusoidal bone marrow infiltration and splenic marginal zone lymphoma: a quantitative study , 2006, European journal of haematology.

[71]  A. Pileri,et al.  High-dose chemotherapy and autologous bone marrow transplantation compared with MACOP-B in aggressive B-cell lymphoma. , 1997, The New England journal of medicine.

[72]  M. S. Lewis,et al.  An international evaluation of CODOX-M and CODOX-M alternating with IVAC in adult Burkitt's lymphoma: results of United Kingdom Lymphoma Group LY06 study. , 2002, Annals of oncology : official journal of the European Society for Medical Oncology.

[73]  B. Nathwani,et al.  AIDS-related Burkitt's lymphoma versus diffuse large-cell lymphoma in the pre-highly active antiretroviral therapy (HAART) and HAART eras: significant differences in survival with standard chemotherapy. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[74]  X. Mariette,et al.  Regression of splenic lymphoma with villous lymphocytes after treatment of hepatitis C virus infection. , 2002, The New England journal of medicine.

[75]  D. Weisenburger,et al.  New approach to classifying non-Hodgkin's lymphomas: clinical features of the major histologic subtypes. Non-Hodgkin's Lymphoma Classification Project. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[76]  S. Hamilton-Dutoit,et al.  Characteristics of Hodgkin's lymphoma after infectious mononucleosis. , 2003, The New England journal of medicine.

[77]  W. Wilson,et al.  The role of rituximab and chemotherapy in aggressive B-cell lymphoma: a preliminary report of dose-adjusted EPOCH-R. , 2002, Seminars in oncology.

[78]  A. Varghese,et al.  Clinical stage IA (limited patch and plaque) mycosis fungoides. A long-term outcome analysis. , 1996, Archives of dermatology.

[79]  Elaine S. Jaffe,et al.  A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. , 1994, Blood.

[80]  D. Weisenburger,et al.  Use of hair coloring products and the risk of lymphoma, multiple myeloma, and chronic lymphocytic leukemia. , 1992, American journal of public health.

[81]  G. Klein,et al.  DNA of Epstein-Barr virus detected in tissue of Burkitt's lymphoma and nasopharyngeal carcinoma. , 1973, Proceedings of the National Academy of Sciences of the United States of America.

[82]  L. Wilson,et al.  The changing survival of patients with mycosis fungoides , 1999, Cancer.

[83]  L. Kalish,et al.  Patterns of presentation of Hodgkin disease. Implications for etiology and pathogenesis , 1993, Cancer.

[84]  H. Greenberg Paraneoplastic cerebellar degeneration , 2004, Journal of Neuro-Oncology.

[85]  A. Zelenetz,et al.  Primary mediastinal large B‐cell lymphoma: optimal therapy and prognostic factor analysis in 141 consecutive patients treated at memorial Sloan Kettering from 1980 to 1999 , 2005, British journal of haematology.

[86]  T M Grogan,et al.  Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. , 1993, The New England journal of medicine.

[87]  V. Beral,et al.  Highly active antiretroviral therapy and incidence of cancer in human immunodeficiency virus-infected adults. , 2000 .

[88]  P. Brousset,et al.  Demonstration of Epstein-Barr virus replication in Reed-Sternberg cells of Hodgkin's disease. , 1993, Blood.

[89]  X. Mariette,et al.  Splenic lymphoma with villous lymphocytes, associated with type II cryoglobulinemia and HCV infection: a new entity? , 2005, Blood.

[90]  Carl Blomqvist,et al.  Prognostic impact of immunohistochemically defined germinal center phenotype in diffuse large B-cell lymphoma patients treated with immunochemotherapy. , 2007, Blood.

[91]  L. Specht,et al.  Different histopathological subtypes of Hodgkin lymphoma show significantly different levels of FDG uptake , 2006, Hematological oncology.

[92]  R. Gascoyne,et al.  Long‐term disease‐free survival of patients with advanced follicular lymphoma after allogeneic bone marrow transplantation , 2004, British journal of haematology.

[93]  R. Willemze,et al.  Mycosis fungoides: disease evolution and prognosis of 309 Dutch patients. , 2000, Archives of dermatology.

[94]  S. Horning,et al.  Stanford V and radiotherapy for locally extensive and advanced Hodgkin's disease: mature results of a prospective clinical trial. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[95]  T J Hamblin,et al.  Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia. , 1999, Blood.

[96]  M. Shoukri,et al.  Primary diagnosis and REAL/WHO classification of non‐Hodgkin's lymphoma by fine‐needle aspiration: Cytomorphologic and immunophenotypic approach , 2003, Diagnostic cytopathology.

[97]  R. Fisher,et al.  Effect of Adding Rituximab to Three Cycles of CHOP Plus Invoved-Field Radiotherapy for Limited-Stage Aggressive Diffuse B-Cell Lymphoma (SWOG-0014). , 2004 .

[98]  C. Craddock,et al.  Clinical evidence of a graft-versus-Hodgkin's-lymphoma effect after reduced-intensity allogeneic transplantation , 2005, The Lancet.

[99]  N. Konstantinou,et al.  Pure infradiaphragmatic Hodgkin's lymphoma. Clinical features, prognostic factor and comparison with supradiaphragmatic disease. , 2006, Haematologica.

[100]  Meland,et al.  The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. , 2002, The New England journal of medicine.

[101]  A. Alavi,et al.  Utility of FDG-PET scanning in lymphoma by WHO classification. , 2003, Blood.

[102]  A. Jemal,et al.  Cancer Statistics, 2007 , 2007, CA: a cancer journal for clinicians.

[103]  K. van Besien,et al.  Primary mediastinal B-cell lymphoma: a review of pathology and management. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[104]  C. Gisselbrecht,et al.  Adult Burkitt's and Burkitt-like non-Hodgkin's lymphoma--outcome for patients treated with high-dose therapy and autologous stem-cell transplantation in first remission or at relapse: results from the European Group for Blood and Marrow Transplantation. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[105]  R. Advani,et al.  Non‐Hodgkin lymphoma of the breast , 2007, Cancer.

[106]  H Stein,et al.  A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. , 1994, Blood.

[107]  E. Hoster,et al.  Immunochemotherapy with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone significantly improves response and time to treatment failure, but not long-term outcome in patients with previously untreated mantle cell lymphoma: results of a prospective randomized trial of the Germa , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[108]  A. Zelenetz,et al.  A 2-step comprehensive high-dose chemoradiotherapy second-line program for relapsed and refractory Hodgkin disease: analysis by intent to treat and development of a prognostic model. , 2001, Blood.

[109]  P. Isaacson,et al.  Helicobacter pylori-associated gastritis and primary B-cell gastric lymphoma , 1991, The Lancet.

[110]  S. Tucker,et al.  Long-term results with radiotherapy for Stage I-II follicular lymphomas. , 2001, International journal of radiation oncology, biology, physics.

[111]  J. Raemaekers,et al.  Combined-modality therapy for clinical stage I or II Hodgkin's lymphoma: long-term results of the European Organisation for Research and Treatment of Cancer H7 randomized controlled trials. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[112]  A. Varghese,et al.  Clinical characteristics and long-term outcome of patients with generalized patch and/or plaque (T2) mycosis fungoides. , 1999, Archives of dermatology.

[113]  S. Pileri,et al.  Origin of nodular lymphocyte-predominant Hodgkin's disease from a clonal expansion of highly mutated germinal-center B cells. , 1997, The New England journal of medicine.

[114]  G. Salles,et al.  Incidence, predictive factors, and outcome of lymphoma transformation in follicular lymphoma patients. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[115]  L. Staudt,et al.  The biology of human lymphoid malignancies revealed by gene expression profiling. , 2005, Advances in immunology.

[116]  Todd,et al.  Diffuse large B-cell lymphoma outcome prediction by gene-expression profiling and supervised machine learning , 2002, Nature Medicine.

[117]  J. Bosq,et al.  Primary Breast Lymphoma , 2003, Leukemia & lymphoma.

[118]  H. Tsukuma,et al.  Risk of non‐Hodgkin's lymphoma in patients with hepatitis C virus infection , 1999, International journal of cancer.

[119]  D. Reece,et al.  Intensive therapy with cyclophosphamide, carmustine, etoposide +/- cisplatin, and autologous bone marrow transplantation for Hodgkin's disease in first relapse after combination chemotherapy. , 1994, Blood.

[120]  N. Harris,et al.  Mucosa‐associated lymphoid tissue lymphoma of the stomach , 1999, Cancer.

[121]  J. Srigley,et al.  Mediastinal large-cell lymphoma. , 1992, Canadian Association of Radiologists journal = Journal l'Association canadienne des radiologistes.

[122]  T. Golub,et al.  The molecular signature of mediastinal large B-cell lymphoma differs from that of other diffuse large B-cell lymphomas and shares features with classical Hodgkin lymphoma. , 2003, Blood.

[123]  S. Horning,et al.  The natural history of initially untreated low-grade non-Hodgkin's lymphomas. , 1984, The New England journal of medicine.

[124]  B. Nathwani,et al.  A clinical evaluation of the International Lymphoma Study Group Classification of non-Hodgkin's lymphoma: a report of the Non-Hodgkin's Lymphoma Classification Project , 1997 .

[125]  D. Winfield,et al.  Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin's disease: results of a BNLI randomised trial , 1993, The Lancet.

[126]  Ash A. Alizadeh,et al.  Prediction of survival in diffuse large-B-cell lymphoma based on the expression of six genes. , 2004, The New England journal of medicine.

[127]  M. Carrington,et al.  HLA-DR, HLA-DQ, and TAP genes in familial Hodgkin disease. , 2002, Blood.

[128]  S. Kvaløy,et al.  Central nervous system involvement following diagnosis of non-Hodgkin's lymphoma: a risk model. , 2002, Annals of oncology : official journal of the European Society for Medical Oncology.

[129]  A. Varghese,et al.  Long-term outcome of 525 patients with mycosis fungoides and Sezary syndrome: clinical prognostic factors and risk for disease progression. , 2003, Archives of dermatology.

[130]  B. Christensen,et al.  Diffuse large B‐cell lymphoma: clinical implications of extranodal versus nodal presentation – a population‐based study of 1575 cases , 2004, British journal of haematology.

[131]  T. Molina,et al.  ACVBP versus CHOP plus radiotherapy for localized aggressive lymphoma. , 2005, The New England journal of medicine.

[132]  M. Pfreundschuh,et al.  Four versus six courses of a dose‐escalated cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) regimen plus etoposide (megaCHOEP) and autologous stem cell transplantation , 2006, Cancer.

[133]  F. Collin,et al.  Modification of Kiel and working formulation classifications for improved survival prediction in non-Hodgkin's lymphoma. , 1987, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[134]  Y. Natkunam,et al.  Rituximab in lymphocyte-predominant Hodgkin disease: results of a phase 2 trial. , 2003, Blood.

[135]  J. Itami,et al.  Extranodal natural killer/T‐cell lymphoma, nasal type , 2006, Cancer.

[136]  A. López-Guillermo,et al.  CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group. , 2006, The Lancet. Oncology.

[137]  A. Staines,et al.  The increasing incidence of non-Hodgkin's lymphoma (NHL): the possible role of sunlight. , 1994, Leukemia & lymphoma.

[138]  S. de Vos,et al.  Kaposi's sarcoma-associated herpesvirus (KSHV or HHV8) in primary effusion lymphoma: ultrastructural demonstration of herpesvirus in lymphoma cells. , 1996, Blood.

[139]  R. Hoppe,et al.  Nodular and diffuse types of lymphocyte predominance Hodgkin's disease. , 1988, The New England journal of medicine.

[140]  A. Zelenetz,et al.  Phase II Trial of Dose-Dense R-CHOP Followed by Risk-Adapted Consolidation with Either ICE or ICE and ASCT, Based upon the Results of Biopsy Confirmed Abnormal Interim Restaging PET Scan, Improves Outcome in Patients with Advanced Stage DLBCL. , 2006 .

[141]  M. Paulli,et al.  Primary mediastinal large B-cell lymphoma (PMLBCL): long-term results from a retrospective multicentre Italian experience in 138 patients treated with CHOP or MACOP-B/VACOP-B , 2004, British Journal of Cancer.

[142]  D. Weisenburger,et al.  Lymphoma incidence patterns by WHO subtype in the United States, 1992-2001. , 2006, Blood.

[143]  S. Pileri,et al.  Early positron emission tomography (PET) restaging: a predictive final response in Hodgkin's disease patients. , 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

[144]  D. Oscier,et al.  Multivariate analysis of prognostic factors in CLL: clinical stage, IGVH gene mutational status, and loss or mutation of the p53 gene are independent prognostic factors. , 2002, Blood.

[145]  Adrian Wiestner,et al.  A gene expression-based method to diagnose clinically distinct subgroups of diffuse large B cell lymphoma , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[146]  S. Franceschi,et al.  Epidemiological, biological and clinical features of HIV-related lymphomas in the era of highly active antiretroviral therapy. , 2000, AIDS.

[147]  Markus Loeffler,et al.  Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60). , 2008, The Lancet. Oncology.

[148]  E. Giné,et al.  Diffuse large B-cell lymphoma: clinical and biological characterization and outcome according to the nodal or extranodal primary origin. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[149]  R. Coutinho,et al.  Highly active antiretroviral therapy and incidence of cancer in human immunodeficiency virus-infected adults , 2000 .

[150]  M. Tiemann,et al.  Blastoid variant of mantle cell lymphoma: late progression from classical mantle cell lymphoma and quantitation of minimal residual disease , 2005, European journal of haematology.

[151]  K. Hemminki,et al.  Familial risk for non-Hodgkin lymphoma and other lymphoproliferative malignancies by histopathologic subtype: the Swedish Family-Cancer Database. , 2005, Blood.

[152]  M. M. Mac Manus,et al.  Is radiotherapy curative for stage I and II low-grade follicular lymphoma? Results of a long-term follow-up study of patients treated at Stanford University. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[153]  Konrad Donhuijsen Patterns of presentation of Hodgkin disease , 1993, Cancer.

[154]  J. Armitage,et al.  Prognostic factors for response and survival after high-dose cyclophosphamide, carmustine, and etoposide with autologous bone marrow transplantation for relapsed Hodgkin's disease. , 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[155]  S. Horning,et al.  High-dose therapy and autologous hematopoietic progenitor cell transplantation for recurrent or refractory Hodgkin's disease: analysis of the Stanford University results and prognostic indices. , 1997, Blood.

[156]  D. Weisenburger,et al.  Agricultural pesticide use, familial cancer, and risk of non-Hodgkin lymphoma. , 2004, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology.

[157]  A. Neugut,et al.  Incidence rates of the major leukemia subtypes among U.S. Hispanics, Blacks, and non-Hispanic Whites , 2006, Leukemia & lymphoma.

[158]  V. Diehl,et al.  Standard and increased-dose BEACOPP chemotherapy compared with COPP-ABVD for advanced Hodgkin's disease. , 2003, The New England journal of medicine.

[159]  J. Askling,et al.  Malignant Lymphomas in Autoimmunity and Inflammation: A Review of Risks, Risk Factors, and Lymphoma Characteristics , 2006, Cancer Epidemiology Biomarkers & Prevention.